Sep 2026· Critical reviews in oncology/hematology· pp.
105626
· 0 citations· 75 references
Medicine
TL;DR
It is proposed that B cells support anti-tumor immunity when integrated into organized lymphoid niches and engaged in productive T cell-B cell cooperation, whereas they promote immune escape when redirected toward regulatory programs or suppressive myeloid interactions.
Abstract
Tumor-infiltrating B cells are emerging as critical regulators of cancer immunity. Recent single-cell and spatial studies have shown that their functions extend beyond antibody production to include antigen presentation, tertiary lymphoid structure (TLS) organization, T cell modulation, cytokine-mediated regulation, and myeloid crosstalk. However, the clinical and immunological roles of B cells in cancer are highly context-dependent. In some tumors, B cell infiltration, particularly within mature TLSs, is associated with improved survival and enhanced responses to immune checkpoint blockade. In other settings, regulatory B cells or immunosuppressive plasma cells can promote tumor progression by suppressing cytotoxic lymphocytes, reinforcing regulatory immune networks, or cooperating with suppressive myeloid populations. These divergent observations indicate that B cells should not be interpreted as uniformly anti-tumor or pro-tumor. Instead, their functions are shaped by developmental state, spatial localization, inflammatory cues, antigenic specificity, and cellular interaction networks. In this review, we discuss tumor-infiltrating B cells through a context-dependent framework. We propose that B cells support anti-tumor immunity when integrated into organized lymphoid niches and engaged in productive T cell-B cell cooperation, whereas they promote immune escape when redirected toward regulatory programs or suppressive myeloid interactions. Understanding this functional plasticity may help reconcile differences across cancer types and guide the development of B cell-informed biomarkers and therapeutic strategies.
The infiltration of tumors by CD8⁺ T lymphocytes is a critical determinant of antitumor immunity and response to immunotherapy. However, the presence of tumor-specific CD8⁺ T cells does not necessarily translate into effective tumor control, as multiple biological barriers can prevent their recruitment, spatial distrib...
Effector B cell responses in solid malignancies are associated favorable response to immunotherapy. B cells can amplify anti-tumor immune responses via antibody production, antigen presentation, and pro-inflammatory cytokine release; yet B cells in cancer patients and tumor-bearing mice often fail to support these fu...
This review focuses on the intersection of B cell biology and tumor immunometabolism, emphasizing how hypoxia, lactate, nutrient limitation, adenosine, PGE2, kynurenine and B cell-derived γ-aminobutyric acid (GABA) may shape B cell states and their interactions with myeloid and lymphoid cells.
Immune‐cell dynamics within the tumor microenvironment (TME) determine whether immune cells can reach, recognize, and sustain antitumor function against malignant cells under suppressive pressure. These dynamics are shaped by hypoxia, nutrient stress, cytokine and chemokine signaling, stromal architecture, vascular acc...
Pin Guo, Yi-Zhao Xie, R. Song et al.· MedComm· 0 citations
Current evidence supports the view that VISTA should be considered not simply as another inhibitory receptor, but as a dynamically regulated, myeloid-centered checkpoint axis with translational relevance in checkpoint-refractory and immune-excluded tumors.
Sarenur Teki̇ner, R. Karataş, Yaren Alras et al.· Medical Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.